COPD, a common disease - screening withPulmoLife

PulmoLife - COPD Screening Unit

Test the lung parameter FEV1 with PulmoLife.
Screening for chronic obstructive pulmonary disease (COPD)
Results ready in a few seconds.
PulmoLife serves the purpose of an early detection of a chronic obstructive pulmonary disease (COPD).

With about five million patients in Germany alone the chronic obstructive pulmonary disease (COPD) is one of the most underestimated common diseases existing and there is a marked upward trend. The early stage of COPD is often not detected and accordingly remains untreated.

An early diagnosis and the proper therapy of COPD can influence the progression of the disease positively. PulmoLife is excellently suited for a rapid check of pulmonary function and enables an early recognition of potential COPD symptoms.
With PulmoLife, risk patients can be tested for COPD. FEV1 and FEV1% are measured and shown on the display. FEV1 is a significant parameter recommended to be measured for a COPD diagnosis. The relative difference from the preset boundary value helps to evaluate the severity grade1 . Based on the test results PulmoLife then calculates the estimated “age of the lungs2” relative to the deviation from FEV1% preset boundary value. particularly cigarette smokers are shown to what extent their lung damage has already progressed . This motivates the patients to give up smoking. Smokers have the highest risk to develop COPD. Pulmonary function decreases twice as often among smokers than non-smokers. 3

A measurement only takes a few seconds and is therefore ideally suited for public campaigns  like health day events, trade fairs, or other event activities.


1) NICE COPD Guidelines 2004, Thorax 2004:59 (suppl I):1-231
2) Morris JF, Temple W.Spirometrc 'Lung Age' estimation for motivating smoking cessation. Preventative Medicine, 1995; 14 655-662
3) Fletcher C, Peto R. BMJ 1977; I :1645-1648



Do you wish personal consulting service

Service Hotline: